R. Levine and D. Gilliland, Myeloproliferative disorders, Blood, vol.112, issue.6, pp.2190-2198, 2008.
DOI : 10.1182/blood-2008-03-077966

E. Baxter, L. Scott, and P. Campbell, Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders, The Lancet, vol.365, issue.9464, pp.1054-61, 2005.
DOI : 10.1016/S0140-6736(05)74230-6

Y. Pikman, B. Lee, and T. Mercher, MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia, PLoS Medicine, vol.102, issue.7, p.270, 2006.
DOI : 10.1371/journal.pmed.0030270.st001

T. Klampfl, H. Gisslinger, and A. Harutyunyan, Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms, New England Journal of Medicine, vol.369, issue.25, pp.2379-90, 2013.
DOI : 10.1056/NEJMoa1311347

K. Hussein, M. Percy, and M. Mcmullin, Clinical utility gene card for: Hereditary thrombocythemia, European Journal of Human Genetics, vol.92, issue.2, pp.1-5, 2014.
DOI : 10.1038/sj.leu.2404846

A. Mead, M. Rugless, S. Jacobsen, and A. Schuh, Mutation in a Family with Hereditary Thrombocytosis, New England Journal of Medicine, vol.366, issue.10, pp.967-976, 2012.
DOI : 10.1056/NEJMc1200349

A. Mead, O. Chowdhury, and C. Pecquet, Impact of isolated germline JAK2V617I mutation on human hematopoiesis, Blood, vol.121, issue.20, pp.4156-65, 2013.
DOI : 10.1182/blood-2012-05-430926

C. Mullighan, J. Zhang, and R. Harvey, JAK mutations in high-risk childhood acute lymphoblastic leukemia, Proceedings of the National Academy of Sciences, vol.106, issue.23, pp.9414-9422, 2009.
DOI : 10.1073/pnas.0811761106

N. Ghilardi and R. Skoda, The Leptin Receptor Activates Janus Kinase 2 and Signals for Proliferation in a Factor-Dependent Cell Line, Molecular Endocrinology, vol.11, issue.4, pp.393-402, 1997.
DOI : 10.1210/mend.11.4.9907

C. Carter-su and L. Smit, Signaling via JAK tyrosine kinases: growth hormone receptor as a model system, Recent Prog Horm Res, vol.53, pp.61-82, 1998.

A. Penas-steinhardt, M. Tellechea, L. Gomez-rosso, F. Brites, G. Frechtel et al., Association of common variants in JAK2 gene with reduced risk of metabolic syndrome and related disorders, BMC Medical Genetics, vol.55, issue.4, p.166, 2011.
DOI : 10.2337/diabetes.55.04.06.db05-1265

W. Ma, H. Kantarjian, and X. Zhang, Mutation Profile of JAK2 Transcripts in Patients with Chronic Myeloproliferative Neoplasias, The Journal of Molecular Diagnostics, vol.11, issue.1, pp.49-53, 2009.
DOI : 10.2353/jmoldx.2009.080114

E. Feener, F. Rosario, S. Dunn, Z. Stancheva, M. Myers et al., Tyrosine Phosphorylation of Jak2 in the JH2 Domain Inhibits Cytokine Signaling, Molecular and Cellular Biology, vol.24, issue.11, pp.4968-78, 2004.
DOI : 10.1128/MCB.24.11.4968-4978.2004

M. Feenstra, J. Nivarthi, H. Gisslinger, and H. , Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms, Blood, vol.127, issue.3, pp.325-357, 2016.
DOI : 10.1182/blood-2015-07-661835

N. Xu, L. Ding, and C. Yin, A report on the co-occurrence of JAK2V617F and CALR mutations in myeloproliferative neoplasm patients, Annals of Hematology, vol.14, issue.10, pp.865-872, 2015.
DOI : 10.1007/s00277-014-2248-0